HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

WIB801C

has platelet aggregation inhibitory activity; CE-WIB801C is cordycepin-enriched; isolated from Cordyceps militaris

Also Known As:

CE-WIB801C

Networked: 4 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Plant Preparations: 622
    - Plant Extracts: 3916
      - WIB801C: 4
Pharmaceutical Preparations
- Plant Extracts: 3916
  - WIB801C: 4

Experts

1.	Kim, Hyun-Hong: 3 articles (01/2015 - 05/2014)
2.	Kim, Jong-Lae: 3 articles (01/2015 - 05/2014)
3.	Lee, Dong-Ha: 3 articles (01/2015 - 05/2014)
4.	Park, Hwa-Jin: 3 articles (01/2015 - 05/2014)
5.	Lee, Jong-Jin: 2 articles (01/2015 - 05/2014)
6.	Lim, Deok Hwi: 2 articles (01/2015 - 01/2015)
7.	Cho, Geum-Sil: 1 article (06/2016)
8.	Hwang, Sunyoung: 1 article (06/2016)
9.	Ju, Chung: 1 article (06/2016)
10.	Kim, Hoon J: 1 article (06/2016)

Related Diseases

1.	Ischemic Stroke 06/20/2016 - "In the present study, therefore, we investigated the potential therapeutic efficacy of WIB801C, the standardized extract of Cordyceps militaris, for treatment of cerebral ischemic stroke. "
2.	Ischemia 06/20/2016 - "WIB801C also improved survival rates over 34 days after ischemia onset. "
3.	Infarction (Infarctions) 06/20/2016 - "A significant reduction in infarct volume and neurobehavioral deficits by WIB801C was also observed in rats subjected to pMCAO. "
4.	Atherosclerosis 01/01/2015 - "Therefore, in this study, we demonstrate that CE-WIB801C may have a preventive or therapeutic potential for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease. " 05/01/2014 - "In this study, we demonstrate that CE-WIB801C with cAMP-dependent Ca(2+)-antagonistic antiplatelet effects may have preventive or therapeutic potential for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease. " 01/01/2015 - "These results strongly indicate that CE-WIB801C and cordycepin may have preventive or therapeutic potential for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease. "
5.	Thrombosis (Thrombus) 01/01/2015 - "Therefore, in this study, we demonstrate that CE-WIB801C may have a preventive or therapeutic potential for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease. " 05/01/2014 - "In this study, we demonstrate that CE-WIB801C with cAMP-dependent Ca(2+)-antagonistic antiplatelet effects may have preventive or therapeutic potential for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease. " 01/01/2015 - "These results strongly indicate that CE-WIB801C and cordycepin may have preventive or therapeutic potential for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease. "

Related Drugs and Biologics

1.	cordycepin